LogicBio Therapeutics to Present at Upcoming Investor Conferences
12. November 2020 16:05 ET
|
LogicBio Therapeutics
LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery today...
LogicBio Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
09. November 2020 06:30 ET
|
LogicBio Therapeutics
- IND for LB-001 in methylmalonic acidemia (MMA) cleared in August 2020, with first patient in Phase 1/2 SUNRISE trial expected to be enrolled in early 2021- Fast Track designation for LB-001 in MMA...
LogicBio Therapeutics Receives FDA Fast Track Designation for LB-001 for the Treatment of Methylmalonic Acidemia (MMA)
04. November 2020 07:45 ET
|
LogicBio Therapeutics
LEXINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted...
LogicBio Therapeutics Announces Appointment of Veteran Biotech Executive Mariana Nacht, Ph.D., as Chief Scientific Officer and Kyle Chiang, Ph.D., Promoted to Chief Operating Officer
03. November 2020 16:05 ET
|
LogicBio Therapeutics
LEXINGTON, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted...
LogicBio Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
05. Oktober 2020 11:12 ET
|
LogicBio Therapeutics
LEXINGTON, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted...
LogicBio Therapeutics Announces Pricing of Public Offering of Common Stock
01. Oktober 2020 09:10 ET
|
LogicBio Therapeutics
LEXINGTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted...
LogicBio Therapeutics Announces Proposed Public Offering of Common Stock
30. September 2020 16:01 ET
|
LogicBio Therapeutics
LEXINGTON, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted...
LogicBio Therapeutics to Present at the Jefferies Virtual Gene Editing/Therapy Summit October 2, 2020
25. September 2020 19:49 ET
|
LogicBio Therapeutics
LEXINGTON, Mass., Sept. 25, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric...
LogicBio Therapeutics to Present at the 4th Annual Chardan Virtual Genetic Medicines Conference October 5, 2020
25. September 2020 19:47 ET
|
LogicBio Therapeutics
LEXINGTON, Mass., Sept. 25, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric...
LogicBio Therapeutics Announces SUNRISE Phase 1/2 Clinical Design for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients
10. August 2020 06:35 ET
|
LogicBio Therapeutics
– LogicBio’s First IND Clearance Leveraging GeneRide, an In Vivo Homologous Recombination-based Genome Editing Platform – – Enrollment to Start with Patients as Young as 3 Years Old, De-escalating...